Colorectal Cancer Dataset in Xijing Hospital From 2011
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorXijing Hospital
About this trial
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
2. Visit our center with complete medical records and pathological information;
3. Colorectal cancer patients diagnosed between 2013 and 2023.
Disqualifiers
1. The patient has other colorectal malignancies other than adenocarcinoma;
2. Malignant tumors adjacent to organs invading the colon and rectum;
3. Malignant tumors from distant organs metastasize to the colon and rectum;
4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Trial population
Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
40,000 Participants
are grouped into 1 trial groupGroup A: colorectal cancer
Trial outcomes
Primary outcomes
1
overall survival
to dead or lost to follow
Time frame
from date of diagnosis until the date of death from any cause, assessed up to 120 months2
DFS
disease-free survival
Time frame
from date of diagnosis until the first documented progression or recurrence, assessed up to 120 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov